Bayer buys BlueRock in USD 600 million bet on stem cell therapies Medical Dialogues Bureau9 Aug 2019 9:00 AM ISTFRANKFURT: German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up...
China vaccine scandal ripples through domestic market, threatens global push Ruby Khatun Khatun24 July 2018 9:45 AM ISTSHANGHAI: A vaccine scandal in China, which has hit a nerve in the country and prompted quick reactions from leaders in Beijing, is sending ripples...